Health Care·Biotechnology·$8.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | +3.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.50 | N/A | +3.28% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on their long-term goals and is optimistic about future opportunities. They acknowledged the challenges faced in the current quarter.
Management highlighted ongoing research efforts and potential future developments.
They expressed commitment to advancing their pipeline despite current losses.
Cytokinetics reported a loss per share that was slightly better than expected, but did not provide revenue figures or future guidance. The stock fell by 1.6% after the earnings report, reflecting investor caution amid ongoing losses and uncertainty about the company's next steps. The lack of revenue data may have contributed to the stock's decline as investors seek clearer financial indicators.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AT&T INC
Oct 28, 2019